Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of STN1014100 ophthalmic solution in patients with dry eye
jRCT2031250105Phase 2Recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of STN1014100 in dry eye syndrome (DED) (4 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Change from baseline in dry eye signs. Started May 2025; status: recruiting.
02
Drugs
STN1014100
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on jRCT2031250105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250105.